This study looks at adding a new medicine called **tirzepatide** to another medicine, **ixekizumab**, which is already being used to treat **psoriatic arthritis (PsA)**. PsA is a kind of arthritis that affects some people who have skin disease called psoriasis. The study is for people who are overweight or have obesity, which means having too much body weight, and have other health issues like high blood pressure or diabetes. Participants should have been on ixekizumab for about 3 months before starting tirzepatide.

The study will last for up to 12 months, and participants cannot have used tirzepatide before or have certain health problems like **type 1 diabetes** or **pancreatitis**.

• The study lasts up to 12 months.
• Participants must be overweight or have obesity with some health issues.
• Cannot have used tirzepatide or similar medicines before.